LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

MacroGenics Inc

Отворен

СекторЗдравеопазване

1.25 -1.57

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.24

Максимум

1.29

Ключови измерители

By Trading Economics

Приходи

-26M

-41M

Продажби

-4.5M

13M

P/E

Средно за сектора

38.83

50.291

EPS

-0.65

Марж на печалбата

-311.067

Служители

341

EBITDA

-27M

-39M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+274.02% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-70M

83M

Предишно отваряне

2.82

Предишно затваряне

1.25

Настроения в новините

By Acuity

50%

50%

154 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.06.2025 г., 23:49 ч. UTC

Печалби

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26.06.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26.06.2025 г., 21:30 ч. UTC

Печалби

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26.06.2025 г., 21:07 ч. UTC

Печалби

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26.06.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26.06.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26.06.2025 г., 23:34 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26.06.2025 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26.06.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers Will No Longer Receive Earnings From BWP Management

26.06.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26.06.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26.06.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26.06.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26.06.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26.06.2025 г., 23:19 ч. UTC

Придобивния, сливания и поглъщания

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26.06.2025 г., 22:06 ч. UTC

Печалби

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26.06.2025 г., 21:15 ч. UTC

Печалби

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26.06.2025 г., 21:07 ч. UTC

Печалби

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26.06.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26.06.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26.06.2025 г., 21:06 ч. UTC

Пазарно говорене

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26.06.2025 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26.06.2025 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26.06.2025 г., 20:52 ч. UTC

Печалби

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26.06.2025 г., 20:51 ч. UTC

Печалби

Correct: Nike 4Q Net $211M, Not $200M >NKE

26.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

274.02% нагоре

12-месечна прогноза

Среден 4.75 USD  274.02%

Висок 8 USD

Нисък 3 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

2

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

154 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.